



2021 Taipei International Breast Cancer Symposium

台北國際乳癌研討會

Transforming clinical treatment in HER2 positive breast cancer with the new subcutaneous dosage

Sara M. Tolaney

Senior Physician, Dana-Farber Cancer Institute,
Physician, Brigham and Women's Hospital,
Associate Professor, Harvard Medical School,
Boston, MA, U.S.A.

Trastuzumab and Pertuzumab, with chemotherapy, has become standard of care for treatment of metastatic HER2+ breast cancer and for treatment of node-positive early stage HER2+ disease. Subcutaneous administration of antibody therapy can offer patients a more convenient and faster administration of therapy. The subcutaneous (SQ) version of trastuzumab and pertuzumab combines fixed doses of the two agents, plus hyaluronidase, an enzyme that helps the body absorb the medications, into one vial. Randomized studies have demonstrated the SQ version is associated with similar efficacy, and better tolerability. These data will be reviewed in detail in this presentation, along with case studies.